As diabetes care continues to be a significant focus, innovative treatments are emerging . Retatrutide, Tirzepatide, and Semaglutide represent a exciting evolution in GLP-1 receptor agonist medications. While https://one-bookmark.com/story22097270/the-new-drug-vs-tirzepatide-vs-semaglutide-a-direct-analysis